Business Wire

Fishawack Acquires Creative Consultancy Blue Latitude Health

Share

The Fishawack Group of Companies, one of the world’s largest independent medical communications and medical marketing organizations, has acquired Blue Latitude Health, based in London, UK, and New York, USA. Blue Latitude Health is a creative consultancy combining the commercial focus of a consultancy with the creative vision of an agency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181209005023/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dominic Miller, Fred Bassett, Oliver Dennis (back row from left to right), Martin Brass, Gail Flockhart (front row from left to right). (Photo: Business Wire)

“In 2016, we set out our vision to form a major new force in the global creative agency space that would make us as strong in the creative arena as we already are in medical communications,” explained Oliver Dennis , Chief Executive Officer of the Fishawack Group. “With three acquisitions in this space in the last 16 months, I think we’ve firmly announced our intention to achieve this goal. We were actively looking for a consultancy that could bring strategic and customer experience expertise to our portfolio and Blue Latitude Health fits perfectly.”

“To enable us to continue to grow and provide existing and future clients with a stronger offering, we needed to find a partner who both shared our values and matched our ambition,” stated Martin Brass , Managing Director of Blue Latitude Health. “We believe we have found this partner in Fishawack.”

Fred Bassett , Head of Strategy and Co-founder of Blue Latitude Health, added, “We are thrilled to join an organization with the global scale and extended services in medical and scientific communications that Fishawack offers.”

“Many of our clients are wanting a partner that has specialist global capabilities both commercially and medically, and can ensure alignment of communication objectives,” commented Gail Flockhart , Group Managing Director of Fishawack. “Blue Latitude Health has a deep strategic consulting capability and brings us a base in New York City, from which we can continue to expand our East Coast creative and medical communications teams.”

Fishawack received corporate finance and legal support from Rick Stark and Phil Hall of KPMG and George Danczak and James Finney of Addleshaw Goddard LLP (UK), respectively.

For more information about the Fishawack Group, please contact Gail Flockhart, Group Managing Director, at gail.flockhart@fishawack.com . For more information about Blue Latitude Health, please contact Martin Brass, Managing Director, at martin.brass@bluelatitude.com .

About the Fishawack Group

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in the UK (Knutsford, Oxford, London, and Brighton), the USA (Philadelphia, PA, and San Diego, CA), Switzerland, and India (Hyderabad).

Fishawack comprises two international divisions, Fishawack Medical Communications, developing and delivering services in the fields of medical communications, scientific engagement, publications, market access, strategic consultancy, and thought leader consultancy, and Fishawack Creative, offering strategic planning, creative development, advertising and promotion, and tactical execution.

We have built our reputation on excellence, creativity, and transparency.

About Blue Latitude Health

Blue Latitude Health is a creative consultancy, made for modern healthcare. We combine the commercial focus of a consultancy with the creative vision of an agency, unlocking the potential in products and services that save and transform lives.

Focused on the commercialization of healthcare innovations, we operate globally and regionally at a brand, portfolio and organizational level. We have extensive end-to-end experience in launching breakthrough portfolios, services and brands, and helping our clients to map future customer and patient needs, as well as developing and executing winning commercial strategies.

Blue Latitude Health was founded in 2003 and has offices in London, UK, and New York, USA.

For more information, visit our website at www.bluelatitude.com

Fishawack Group of Companies

www.fishawack.com
LinkedIn: Fishawack Group of Companies
Twitter: @Fishawack

Headquarters:

No. 3 Booths Park, Chelford Road, Knutsford, WA16 8GS, UK
Tel: +44 1565 756600

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fishawack Group
Gail Flockhart, Group Managing Director
gail.flockhart@fishawack.com

Blue Latitude Health
Martin Brass, Managing Director
martin.brass@bluelatitude.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 14:30:00 EEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

Sealing System launches: XIO – Intelligent Farming26.4.2024 13:17:00 EEST | Press release

XIO – Intelligent Farming, specializes in logistics systems for insect protein production. XIO is a new business unit within Sealing System A/S, one of the leading providers of automated end-of-line packaging lines in Scandinavia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240426832303/en/ Robotic solution handling Black Soldier Fly Larvae (Photo: Business Wire) “At Sealing System A/S, we believe that practical innovation is the engine of real-world change. With the establishment of, XIO - Intelligent Farming, we are setting new industry standards, emphasizing the importance of intralogistics in the field of insect protein production, and proudly leading the way.” Ole Jensen CEO, Sealing System A/S XIO – Intelligent Farming provides solutions serving various aspects of the insect production, including fully automatic logistics systems, comprehensive data tracking, transfer trolleys and shuttles, as well as robot systems

Tecnotree Achieves Strong Q1 2024 Results with Sustained Revenue Growth and Enhanced Profitability26.4.2024 11:46:00 EEST | Press release

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the first quarter of 2024, demonstrating solid growth with a 4.7% increase in revenue. The company maintained its momentum in driving global sales of its digital platform, in the first quarter of 2024, completing many AIML and digital transformations to key customers, resulting in a significant increase in revenue. The growth was primarily driven by new wins in the LATAM region, while EMEA and APAC regions remain growing markets for the digital platform. Key Q1 Highlights of the financial results: Net sales increased 4.7% to EUR 16.3 (15.5) million. Operating results increased by 22.3% to EUR 4.4 (3.6) million. Earnings per share EUR 0.01 (0.01). Order book at the end of the period increased by 10.3% to EUR 74.8 (67.8) million. Tecnotree achieved several notable milestones in the first quarter. The company solidified its position as a trusted par

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye